Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
Identifieur interne : 000E67 ( Main/Curation ); précédent : 000E66; suivant : 000E68Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
Auteurs : Kaushik Subramanian [Inde] ; Anuradha Nalli [Inde] ; Vinitha Senthil [Inde] ; Saurabh Jain [Inde] ; Aravind Nayak [Inde] ; Amit Bhat [République populaire de Chine]Source :
- Advances in therapy [ 1865-8652 ] ; 2020.
Descripteurs français
- KwdFr :
- Anticorps monoclonaux humanisés (usage thérapeutique), Antiviraux (usage thérapeutique), Association de médicaments (MeSH), Betacoronavirus (MeSH), Guides de bonnes pratiques cliniques comme sujet (MeSH), Hormones corticosurrénaliennes (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunisation passive (MeSH), Infections à coronavirus (thérapie), Infections à coronavirus (traitement médicamenteux), Pandémies (MeSH), Pneumopathie virale (thérapie).
- MESH :
- thérapie : Infections à coronavirus, Pneumopathie virale.
- traitement médicamenteux : Infections à coronavirus.
- usage thérapeutique : Anticorps monoclonaux humanisés, Antiviraux, Hormones corticosurrénaliennes, Hydroxychloroquine.
- Association de médicaments, Betacoronavirus, Guides de bonnes pratiques cliniques comme sujet, Humains, Immunisation passive, Pandémies.
English descriptors
- KwdEn :
- Adrenal Cortex Hormones (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (MeSH), COVID-19 (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (therapy), Drug Therapy, Combination (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunization, Passive (MeSH), Pandemics (MeSH), Pneumonia, Viral (therapy), Practice Guidelines as Topic (MeSH), SARS-CoV-2 (MeSH).
- MESH :
- chemical , therapeutic use : Adrenal Cortex Hormones, Antibodies, Monoclonal, Humanized, Antiviral Agents, Hydroxychloroquine.
- drug therapy : Coronavirus Infections.
- therapy : Coronavirus Infections, Pneumonia, Viral.
- Betacoronavirus, COVID-19, Drug Therapy, Combination, Humans, Immunization, Passive, Pandemics, Practice Guidelines as Topic, SARS-CoV-2.
Abstract
BACKGROUND
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a serious health concern. Repurposing of existing drugs indicated for other conditions seems to be the first choice for immediate therapeutic management. The quality of early evidence favoring the different treatment options needs to be apprised for informed decision-making.
METHODS
In this systematic literature review, we apprised the quality of available evidence for different therapeutic options and also the basis for different treatment guidelines. To include all studies that are in different stages of publication, we also included studies from the preprint servers BioRxiv and MedRxiv and published studies from PubMed.
RESULTS
We retrieved 5621 articles and included 22 studies for the systematic review. Based on our study, chloroquine/hydroxychloroquine, either alone or in combination with azithromycin, remdesivir, corticosteroids, convalescent sera, ritonavir/lopinavir, tocilizumab and arbidol were evaluated as therapeutic options. The data from different study designs reveal contradictory findings except for convalescent sera for which the evidence available is only from case series. Based on this early evidence, various national guidelines recommend remdesivir, convalescent sera, corticosteroids and hydroxychloroquine in different subsets of patients.
CONCLUSION
Establishing consensus with respect to the end points to be assessed for respiratory viruses may enhance the quality of evidence in case of future pandemics. The systematic review highlighted the lacuna and methodologic deficiency in early clinical evidence and included an update on different therapeutic management guidelines. Further clinical evidence from the ongoing trials may lead to evolution of treatment guidelines with the addition of more therapeutic options.
DOI: 10.1007/s12325-020-01460-5
PubMed: 32809210
PubMed Central: PMC7433267
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000E67
Links to Exploration step
pubmed:32809210Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.</title><author><name sortKey="Subramanian, Kaushik" sort="Subramanian, Kaushik" uniqKey="Subramanian K" first="Kaushik" last="Subramanian">Kaushik Subramanian</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Nalli, Anuradha" sort="Nalli, Anuradha" uniqKey="Nalli A" first="Anuradha" last="Nalli">Anuradha Nalli</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Senthil, Vinitha" sort="Senthil, Vinitha" uniqKey="Senthil V" first="Vinitha" last="Senthil">Vinitha Senthil</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Jain, Saurabh" sort="Jain, Saurabh" uniqKey="Jain S" first="Saurabh" last="Jain">Saurabh Jain</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Nayak, Aravind" sort="Nayak, Aravind" uniqKey="Nayak A" first="Aravind" last="Nayak">Aravind Nayak</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Bhat, Amit" sort="Bhat, Amit" uniqKey="Bhat A" first="Amit" last="Bhat">Amit Bhat</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Lifesystems Consulting (Shanghai) Co. Ltd, Shanghai, China. amit.bhat@indegene.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Indegene Lifesystems Consulting (Shanghai) Co. Ltd, Shanghai</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32809210</idno><idno type="pmid">32809210</idno><idno type="doi">10.1007/s12325-020-01460-5</idno><idno type="pmc">PMC7433267</idno><idno type="wicri:Area/Main/Corpus">000E67</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000E67</idno><idno type="wicri:Area/Main/Curation">000E67</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000E67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.</title><author><name sortKey="Subramanian, Kaushik" sort="Subramanian, Kaushik" uniqKey="Subramanian K" first="Kaushik" last="Subramanian">Kaushik Subramanian</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Nalli, Anuradha" sort="Nalli, Anuradha" uniqKey="Nalli A" first="Anuradha" last="Nalli">Anuradha Nalli</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Senthil, Vinitha" sort="Senthil, Vinitha" uniqKey="Senthil V" first="Vinitha" last="Senthil">Vinitha Senthil</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Jain, Saurabh" sort="Jain, Saurabh" uniqKey="Jain S" first="Saurabh" last="Jain">Saurabh Jain</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Nayak, Aravind" sort="Nayak, Aravind" uniqKey="Nayak A" first="Aravind" last="Nayak">Aravind Nayak</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Pvt Ltd, Bengaluru, India.</nlm:affiliation><country xml:lang="fr">Inde</country><wicri:regionArea>Indegene Pvt Ltd, Bengaluru</wicri:regionArea></affiliation></author><author><name sortKey="Bhat, Amit" sort="Bhat, Amit" uniqKey="Bhat A" first="Amit" last="Bhat">Amit Bhat</name><affiliation wicri:level="1"><nlm:affiliation>Indegene Lifesystems Consulting (Shanghai) Co. Ltd, Shanghai, China. amit.bhat@indegene.com.</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Indegene Lifesystems Consulting (Shanghai) Co. Ltd, Shanghai</wicri:regionArea></affiliation></author></analytic><series><title level="j">Advances in therapy</title><idno type="eISSN">1865-8652</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenal Cortex Hormones (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antiviral Agents (therapeutic use)</term><term>Betacoronavirus (MeSH)</term><term>COVID-19 (MeSH)</term><term>Coronavirus Infections (drug therapy)</term><term>Coronavirus Infections (therapy)</term><term>Drug Therapy, Combination (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunization, Passive (MeSH)</term><term>Pandemics (MeSH)</term><term>Pneumonia, Viral (therapy)</term><term>Practice Guidelines as Topic (MeSH)</term><term>SARS-CoV-2 (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antiviraux (usage thérapeutique)</term><term>Association de médicaments (MeSH)</term><term>Betacoronavirus (MeSH)</term><term>Guides de bonnes pratiques cliniques comme sujet (MeSH)</term><term>Hormones corticosurrénaliennes (usage thérapeutique)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunisation passive (MeSH)</term><term>Infections à coronavirus (thérapie)</term><term>Infections à coronavirus (traitement médicamenteux)</term><term>Pandémies (MeSH)</term><term>Pneumopathie virale (thérapie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adrenal Cortex Hormones</term><term>Antibodies, Monoclonal, Humanized</term><term>Antiviral Agents</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Coronavirus Infections</term><term>Pneumonia, Viral</term></keywords><keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Infections à coronavirus</term><term>Pneumopathie virale</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à coronavirus</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Anticorps monoclonaux humanisés</term><term>Antiviraux</term><term>Hormones corticosurrénaliennes</term><term>Hydroxychloroquine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Betacoronavirus</term><term>COVID-19</term><term>Drug Therapy, Combination</term><term>Humans</term><term>Immunization, Passive</term><term>Pandemics</term><term>Practice Guidelines as Topic</term><term>SARS-CoV-2</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Association de médicaments</term><term>Betacoronavirus</term><term>Guides de bonnes pratiques cliniques comme sujet</term><term>Humains</term><term>Immunisation passive</term><term>Pandémies</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a serious health concern. Repurposing of existing drugs indicated for other conditions seems to be the first choice for immediate therapeutic management. The quality of early evidence favoring the different treatment options needs to be apprised for informed decision-making.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>In this systematic literature review, we apprised the quality of available evidence for different therapeutic options and also the basis for different treatment guidelines. To include all studies that are in different stages of publication, we also included studies from the preprint servers BioRxiv and MedRxiv and published studies from PubMed.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>We retrieved 5621 articles and included 22 studies for the systematic review. Based on our study, chloroquine/hydroxychloroquine, either alone or in combination with azithromycin, remdesivir, corticosteroids, convalescent sera, ritonavir/lopinavir, tocilizumab and arbidol were evaluated as therapeutic options. The data from different study designs reveal contradictory findings except for convalescent sera for which the evidence available is only from case series. Based on this early evidence, various national guidelines recommend remdesivir, convalescent sera, corticosteroids and hydroxychloroquine in different subsets of patients.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Establishing consensus with respect to the end points to be assessed for respiratory viruses may enhance the quality of evidence in case of future pandemics. The systematic review highlighted the lacuna and methodologic deficiency in early clinical evidence and included an update on different therapeutic management guidelines. Further clinical evidence from the ongoing trials may lead to evolution of treatment guidelines with the addition of more therapeutic options.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" IndexingMethod="Curated" Owner="NLM"><PMID Version="1">32809210</PMID><DateCompleted><Year>2020</Year><Month>09</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1865-8652</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>10</Issue><PubDate><Year>2020</Year><Month>10</Month></PubDate></JournalIssue><Title>Advances in therapy</Title><ISOAbbreviation>Adv Ther</ISOAbbreviation></Journal><ArticleTitle>Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.</ArticleTitle><Pagination><MedlinePgn>4107-4131</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12325-020-01460-5</ELocationID><Abstract><AbstractText Label="BACKGROUND">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a serious health concern. Repurposing of existing drugs indicated for other conditions seems to be the first choice for immediate therapeutic management. The quality of early evidence favoring the different treatment options needs to be apprised for informed decision-making.</AbstractText><AbstractText Label="METHODS">In this systematic literature review, we apprised the quality of available evidence for different therapeutic options and also the basis for different treatment guidelines. To include all studies that are in different stages of publication, we also included studies from the preprint servers BioRxiv and MedRxiv and published studies from PubMed.</AbstractText><AbstractText Label="RESULTS">We retrieved 5621 articles and included 22 studies for the systematic review. Based on our study, chloroquine/hydroxychloroquine, either alone or in combination with azithromycin, remdesivir, corticosteroids, convalescent sera, ritonavir/lopinavir, tocilizumab and arbidol were evaluated as therapeutic options. The data from different study designs reveal contradictory findings except for convalescent sera for which the evidence available is only from case series. Based on this early evidence, various national guidelines recommend remdesivir, convalescent sera, corticosteroids and hydroxychloroquine in different subsets of patients.</AbstractText><AbstractText Label="CONCLUSION">Establishing consensus with respect to the end points to be assessed for respiratory viruses may enhance the quality of evidence in case of future pandemics. The systematic review highlighted the lacuna and methodologic deficiency in early clinical evidence and included an update on different therapeutic management guidelines. Further clinical evidence from the ongoing trials may lead to evolution of treatment guidelines with the addition of more therapeutic options.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Subramanian</LastName><ForeName>Kaushik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Indegene Pvt Ltd, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalli</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Indegene Pvt Ltd, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Senthil</LastName><ForeName>Vinitha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Indegene Pvt Ltd, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Saurabh</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Indegene Pvt Ltd, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nayak</LastName><ForeName>Aravind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Indegene Pvt Ltd, Bengaluru, India.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhat</LastName><ForeName>Amit</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Indegene Lifesystems Consulting (Shanghai) Co. Ltd, Shanghai, China. amit.bhat@indegene.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Adv Ther</MedlineTA><NlmUniqueID>8611864</NlmUniqueID><ISSNLinking>0741-238X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName><SupplMeshName Type="Protocol" UI="C000705128">COVID-19 serotherapy</SupplMeshName></SupplMeshList><CitationSubset>T</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007116" MajorTopicYN="N">Immunization, Passive</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="N">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Clinical cure</Keyword><Keyword MajorTopicYN="Y">Evidence</Keyword><Keyword MajorTopicYN="Y">Infectious disease</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">Treatment options</Keyword><Keyword MajorTopicYN="Y">Virological cure</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>06</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32809210</ArticleId><ArticleId IdType="doi">10.1007/s12325-020-01460-5</ArticleId><ArticleId IdType="pii">10.1007/s12325-020-01460-5</ArticleId><ArticleId IdType="pmc">PMC7433267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3390-3396</Citation><ArticleIdList><ArticleId IdType="pubmed">32271456</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101647</Citation><ArticleIdList><ArticleId IdType="pubmed">32247927</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 9;395(10235):1517-1520</Citation><ArticleIdList><ArticleId IdType="pubmed">32311318</ArticleId></ArticleIdList></Reference><Reference><Citation>EClinicalMedicine. 2020 Jun 02;23:100403</Citation><ArticleIdList><ArticleId IdType="pubmed">32632415</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pharm Anal. 2020 Apr;10(2):102-108</Citation><ArticleIdList><ArticleId IdType="pubmed">32282863</ArticleId></ArticleIdList></Reference><Reference><Citation>Med J Aust. 2020 May;212(9):416-420</Citation><ArticleIdList><ArticleId IdType="pubmed">32266987</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation><ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1677-1679</Citation><ArticleIdList><ArticleId IdType="pubmed">32109012</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Mar 24;117(12):6771-6776</Citation><ArticleIdList><ArticleId IdType="pubmed">32054787</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2020 May 26;369:m1936</Citation><ArticleIdList><ArticleId IdType="pubmed">32457027</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation><ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jun 11;382(24):2327-2336</Citation><ArticleIdList><ArticleId IdType="pubmed">32275812</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Jul 17;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Epidemiol. 2011 Apr;64(4):383-94</Citation><ArticleIdList><ArticleId IdType="pubmed">21195583</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation><ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheng Wu Gong Cheng Xue Bao. 2020 Apr 25;36(4):571-592</Citation><ArticleIdList><ArticleId IdType="pubmed">32347053</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Jul 28;71(15):732-739</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):e21-e23</Citation><ArticleIdList><ArticleId IdType="pubmed">32283143</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2020 Apr 30;382(18):1708-1720</Citation><ArticleIdList><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect. 2020 Jul;81(1):e13-e20</Citation><ArticleIdList><ArticleId IdType="pubmed">32283144</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation><ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId></ArticleIdList></Reference><Reference><Citation>Ecancermedicalscience. 2020 Mar 30;14:1023</Citation><ArticleIdList><ArticleId IdType="pubmed">32256706</ArticleId></ArticleIdList></Reference><Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation><ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId></ArticleIdList></Reference><Reference><Citation>Geroscience. 2020 Jun;42(3):1013</Citation><ArticleIdList><ArticleId IdType="pubmed">32363428</ArticleId></ArticleIdList></Reference><Reference><Citation>Travel Med Infect Dis. 2020 May - Jun;35:101738</Citation><ArticleIdList><ArticleId IdType="pubmed">32387409</ArticleId></ArticleIdList></Reference><Reference><Citation>J Korean Med Sci. 2020 Apr 13;35(14):e149</Citation><ArticleIdList><ArticleId IdType="pubmed">32281317</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 Dec 18;1(1):114-127.e3</Citation><ArticleIdList><ArticleId IdType="pubmed">32838355</ArticleId></ArticleIdList></Reference><Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation><ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId></ArticleIdList></Reference><Reference><Citation>Med (N Y). 2020 Dec 18;1(1):105-113.e4</Citation><ArticleIdList><ArticleId IdType="pubmed">32838353</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2020 May 22;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32450107</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>J Thromb Haemost. 2020 Aug;18(8):1995-2002</Citation><ArticleIdList><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nat Commun. 2020 Jan 10;11(1):222</Citation><ArticleIdList><ArticleId IdType="pubmed">31924756</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Respir Med. 2020 May;8(5):436-438</Citation><ArticleIdList><ArticleId IdType="pubmed">32251625</ArticleId></ArticleIdList></Reference><Reference><Citation>Rev Panam Salud Publica. 2020 Mar 20;44:e40</Citation><ArticleIdList><ArticleId IdType="pubmed">32256547</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975</Citation><ArticleIdList><ArticleId IdType="pubmed">32350134</ArticleId></ArticleIdList></Reference><Reference><Citation>Mil Med Res. 2020 Feb 6;7(1):4</Citation><ArticleIdList><ArticleId IdType="pubmed">32029004</ArticleId></ArticleIdList></Reference><Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation><ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Hematol. 2020 Jul;95(7):876-878</Citation><ArticleIdList><ArticleId IdType="pubmed">32282956</ArticleId></ArticleIdList></Reference><Reference><Citation>EBioMedicine. 2020 May;55:102763</Citation><ArticleIdList><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E67 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 000E67 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Curation
|type= RBID
|clé= pubmed:32809210
|texte= Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS-CoV-2: A Systematic Literature Review.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Curation/RBID.i -Sk "pubmed:32809210" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |